SPRO
SPRO
NASDAQ · Biotechnology

Spero Therapeutics Inc

$2.42
+0.12 (+5.22%)
As of Feb 8, 2:09 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 31.09M 30.93M 26.54M
Net Income -7,654,277 -5,880,957 -4,950,304
EPS
Profit Margin -24.6% -19.0% -18.7%
Rev Growth +19.1% +18.4% +23.2%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 27.27M 26.75M 29.13M
Total Equity 81.10M 80.40M 90.84M
D/E Ratio 0.34 0.33 0.32
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -10,459,331 -8,827,347 -7,842,890
Free Cash Flow -9,100,252 -6,633,459 -6,096,996